Login to Your Account

Ahead of Picoplatin SCLC Data, Poniard Opts for $60M CEFF

By Jennifer Boggs

Friday, August 21, 2009
Poniard Pharmaceuticals Inc., set to report Phase III data next quarter for its next-generation platinum chemotherapy picoplatin in small-cell lung cancer, is adding some flexibility to its financial position with a $60 million committed equity financing facility. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription